Boxer Capital Management’s Denali Therapeutics DNLI Stock Holding History

Boxer Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-250,000	Closed	-$3.63M	–	46
2025 Q3	$3.63M	Buy	+250,000	New	+$3.59M	1.16%	21
2025 Q2	–	Sell	-250,000	Closed	-$3.4M	–	24
2025 Q1	$3.4M	Buy	+250,000	New	+$4.79M	1.02%	21

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Boxer Capital Management's DNLI Position: Q4 2025 in Review

Boxer Capital Management sold out of Denali Therapeutics (DNLI) in Q4 2025, closing a stake of 250,000 shares — an estimated $3.63M sold.

Boxer Capital Management first reported a position in DNLI in Q1 2025 and held it in 2 quarters. The position peaked at $3.63M in Q3 2025. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Boxer Capital Management reported no remaining Denali Therapeutics position as of Q4 2025 after selling out during the quarter.
Boxer Capital Management sold 250,000 Denali Therapeutics shares in Q4 2025, an estimated $3.63M.
Boxer Capital Management first reported a position in Denali Therapeutics in Q1 2025 and held it in 2 quarters.
Boxer Capital Management's Denali Therapeutics position peaked at $3.63M in Q3 2025.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Boxer Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.